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PURPOSE: Shortening the duration of antibiotic therapy (ABT) is a key measure in
antimicrobial stewardship. The optimal duration of ABT for treatment of
postoperative intra-abdominal infections (PIAI) in critically ill patients is unknown.
METHODS: A multicentre prospective randomised trial conducted in 21 French
intensive care units (ICU) between May 2011 and February 2015 compared the
efficacy and safety of 8-day versus 15-day antibiotic therapy in critically ill patients
with PIAI. Among 410 eligible patients (adequate source control and ABT on day 0),
249 patients were randomly assigned on day 8 to either stop ABT immediately
(n = 126) or to continue ABT until day 15 (n = 123). The primary endpoint was the
number of antibiotic-free days between randomisation (day 8) and day 28. Secondary
outcomes were death, ICU and hospital length of stay, emergence of multidrug-
resistant (MDR) bacteria and reoperation rate, with 45-day follow-up.
RESULTS: Patients treated for 8 days had a higher median number of antibiotic-free
days than those treated for 15 days (15 [6-20] vs 12 [6-13] days, respectively;
P < 0.0001) (Wilcoxon rank difference 4.99 days [95% CI 2.99-6.00; P < 0.0001).
Equivalence was established in terms of 45-day mortality (rate difference 0.038, 95%
CI - 0.013 to 0.061). Treatments did not differ in terms of ICU and hospital length of
stay, emergence of MDR bacteria or reoperation rate, while subsequent drainages
between day 8 and day 45 were observed following short-course ABT (P = 0.041).
CONCLUSION: Short-course antibiotic therapy in critically ill ICU patients with PIAI
reduces antibiotic exposure. Continuation of treatment until day 15 is not associated
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